Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06908356 · ClinicalTrials.gov registry record · Phase 2
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
A Phase 2 study of Focal Onset Seizure and Primary Generalized Epilepsy, sponsored by Praxis Precision Medicines.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 11
- Study locations
NCT06908356 is a Phase 2 study of Focal Onset Seizure and Primary Generalized Epilepsy that is actively recruiting participants, run by Praxis Precision Medicines. The registered enrollment target is 50 participants. The trial reports 11 study locations across 8 states.
The verdict
NCT06908356, a Phase 2 study of Focal Onset Seizure and Primary Generalized Epilepsy, is actively recruiting participants, sponsored by Praxis Precision Medicines.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures
Conditions Studied
Interventions
- DRUG 30mg PRAX-628
Study Locations (11)
Other
- Praxis Research Site - Heidelberg
- Praxis Research Site - Melbourne
- Praxis Research Site - Madrid
Texas
- Praxis Research Site - Round Rock
- Praxis Research Site - Seabrook
Arizona
- Praxis Research Site - Phoenix
Florida
- Praxis Research Site - Miami Lakes
Maryland
- Praxis Research Site - Bethesda
Missouri
- Praxis Research Site - Chesterfield
New Jersey
- Praxis Research Site - Hackensack
New York
- Praxis Research Site - Middletown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2025-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06908356
The ClinicalTrials.gov registry entry for NCT06908356 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Praxis Precision Medicines, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Focal Onset Seizure appearing as the primary indexed condition, and to 1 intervention - of which 30mg PRAX-628 is the first listed.
NCT06908356 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Other, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT06908356 about?
NCT06908356 is a clinical study titled "An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures". An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures
What is the current status of trial NCT06908356?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-01-10. Estimated completion is 2025-07.
What conditions does trial NCT06908356 study?
This clinical trial studies the following conditions: Focal Onset Seizure, Primary Generalized Epilepsy.
What interventions are being tested in trial NCT06908356?
The interventions under investigation include: 30mg PRAX-628 (DRUG).
Who is sponsoring clinical trial NCT06908356?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06908356 being conducted?
This trial has 11 study locations across Arizona, Florida, Maryland, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Onset Seizure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.